You just read:

New Study By Spherix Global Insights Indicates High Therapy Switching Rates For Multiple Sclerosis Patients In The US And EU, Benefitting Biogen's Tecfidera, Novartis' Gilenya And Sanofi's Aubagio

News provided by

Spherix Global Insights

Apr 14, 2016, 09:34 ET